Verastem Stock Investor Sentiment

VSTM Stock  USD 5.68  0.11  1.97%   
About 59% of all Verastem's investors are looking to take a long position. The analysis of the overall investor sentiment regarding Verastem suggests that some traders are interested. Verastem's investing sentiment overview a quick insight into current market opportunities from investing in Verastem. Many technical investors use Verastem stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  

Verastem Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Verastem can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
59.1%
56.3%
53.0%
53.6%
52.2%
51.1%
50.6%
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
3 days ago at businesswire.com         
Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annu...
businesswire News
3 days ago at businesswire.com         
Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annu...
businesswire News
over a week ago at gurufocus.com         
Alyeska Investment Group Reduces Stake in Verastem Inc
Gurufocus Stories at Macroaxis
over a week ago at gurufocus.com         
BIOTECHNOLOGY VALUE FUND L Ps Strategic Acquisition of Verastem Inc Shares
Gurufocus Stories at Macroaxis
over a week ago at gurufocus.com         
Barclays PLCs Strategic Acquisition of Verastem Inc Shares
Gurufocus Stories at Macroaxis
over a week ago at gurufocus.com         
Balyasny Asset Management L.P. Acquires Significant Stake in Verastem Inc
Gurufocus Stories at Macroaxis
over a week ago at washingtonexaminer.com         
Verastem says Forrester will become its CEO
news
over two weeks ago at news.google.com         
Verastem CEO Dan Paterson sells shares worth 4,890 - Investing.com
Google News at Macroaxis
over two weeks ago at www.macroaxis.com         
Disposition of 858 shares by Paterson Dan of Verastem at 5.7 subject to Rule 16b-3
Macroaxis News
over two weeks ago at thelincolnianonline.com         
Verastem, Inc. Short Interest Update
news
over two weeks ago at thelincolnianonline.com         
B. Riley Issues Positive Forecast for Verastem Stock Price
news
over three weeks ago at gurufocus.com         
Vanguard Group Inc. Increases Stake in Verastem Inc.
Gurufocus Stories at Macroaxis
over three weeks ago at businesswire.com         
Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference
businesswire News
over three weeks ago at news.google.com         
Verastems Next Big Move Key Revelations Expected at Major Biotech Conference - StockTitan
Google News at Macroaxis
over three weeks ago at news.google.com         
Mizuho maintains Verastem stock outperform with 9 target - Investing.com
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Verastem that are available to investors today. That information is available publicly through Verastem media outlets and privately through word of mouth or via Verastem internal channels. However, regardless of the origin, that massive amount of Verastem data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Verastem news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Verastem relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Verastem's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Verastem alpha.

Verastem Performance against Dow Jones

 Price Growth (%)  
JavaScript chart by amCharts 3.21.1512345678910111213141516Dec2025Feb 0204060
JavaScript chart by amCharts 3.21.15Verastem Verastem Dividend Benchmark Dow Jones Industrial
       Timeline  
1
Disposition of 273 shares by Stuglik Brian M of Verastem at 10.38 subject to Rule 16b-3
11/27/2024
2
Disposition of 244 shares by Paterson Dan of Verastem at 4.54 subject to Rule 16b-3
12/16/2024
3
Disposition of 183 shares by Paterson Dan of Verastem at 4.37 subject to Rule 16b-3
12/19/2024
4
Disposition of tradable shares by Daniel Calkins of Verastem at 3.91 subject to Rule 16b-3
12/24/2024
5
Why Is Cancer-Focused Verastem Oncology Stock Trading Higher On Tuesday
12/31/2024
6
Disposition of tradable shares by Daniel Calkins of Verastem at 6.94 subject to Rule 16b-3
01/06/2025
7
Acquisition by Daniel Calkins of 38800 shares of Verastem subject to Rule 16b-3
01/10/2025
8
Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurre...
01/13/2025
9
Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on...
01/14/2025
10
Verastem Oncology Names Matthew E. Ros as Chief Operating Officer
01/15/2025
11
Verastem Appoints Matthew E. Ros as Chief Operating Officer
01/22/2025
12
Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RASMAPK Pathway-Driven Cancers
01/23/2025
13
Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference
01/29/2025
14
Disposition of 858 shares by Paterson Dan of Verastem at 5.7 subject to Rule 16b-3
02/04/2025
15
Verastem says Forrester will become its CEO
02/12/2025
16
Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Womens Cancer
02/20/2025
When determining whether Verastem is a strong investment it is important to analyze Verastem's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Verastem's future performance. For an informed investment choice regarding Verastem Stock, refer to the following important reports:
Check out Verastem Hype Analysis, Verastem Correlation and Verastem Performance.
To learn how to invest in Verastem Stock, please use our How to Invest in Verastem guide.
You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verastem. If investors know Verastem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verastem listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.14)
Revenue Per Share
0.331
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.47)
Return On Equity
(1.37)
The market value of Verastem is measured differently than its book value, which is the value of Verastem that is recorded on the company's balance sheet. Investors also form their own opinion of Verastem's value that differs from its market value or its book value, called intrinsic value, which is Verastem's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verastem's market value can be influenced by many factors that don't directly affect Verastem's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verastem's value and its price as these two are different measures arrived at by different means. Investors typically determine if Verastem is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verastem's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
News Freq…Investor S…